Apremilast with antihistamines for chronic hives
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests whether adding apremilast, a medicine that reduces inflammation, helps people with chronic hives when antihistamines alone aren't enough. It may offer a new option for those who can't use other standard treatments like omalizumab or cyclosporine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had hives for more than 6 weeks, either spontaneous or triggered by something specific.
- Your hives are moderate to severe (a weekly score of 16 or more) despite taking antihistamines for at least 4 weeks.
- You have not been able to use omalizumab or cyclosporine, or they didn't work for you, or you couldn't tolerate them.
- You are not pregnant, planning to become pregnant, or breastfeeding.
- You do not have uncontrolled depression or another uncontrolled psychiatric condition, and you do not have urticarial vasculitis (a type of hives with inflammation of blood vessels).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This study tests a new medication called HRS-3095 to see if it can help people whose chronic hives (itchy welts) do not get better with standard allergy pills. It aims to reduce itching and wheals and improve quality of life.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This study is testing an experimental daily pill called ritlecitinib for adults whose chronic hives don’t go away with standard antihistamines. It may be a new option if your hives are active and you are not on omalizumab or are willing to stop it for several months.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.